Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larry Alphs

Showing results (51-60 of 120) with videos related to

Pageof 12
Sort By:
BMC Psychiatry|February 25, 2014
Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitateJennifer Kern Sliwa, Dong-Jing Fu, Cynthia A Bossie, et al.
Neuropsychiatric Disease and Treatment|September 8, 2012
Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophreniaJennifer Kern Sliwa, Cynthia A Bossie, Dong-Jing Fu, et al.
Innovations in Clinical Neuroscience|July 9, 2015
Comparing Injection Site Pain with Paliperidone Palmitate Versus First-Generation Depot Antipsychotics in Subjects with SchizophreniaSrihari Gopal, Teresa Palermo, Jennifer Kern Sliwa, et al.
International Clinical Psychopharmacology|October 12, 2013
Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparisonDong-Jing Fu, Cynthia A Bossie, Jennifer K Sliwa, et al.
BMC Psychiatry|May 17, 2011
Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trialCynthia A Bossie, Jennifer K Sliwa, Yi-Wen Ma, et al.
Expert Opinion on Pharmacotherapy|April 24, 2014
Onset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophreniaLarry Alphs, Cynthia A Bossie, Dong-Jing Fu, et al.
Neuropsychiatric Disease and Treatment|June 1, 2013
Expansion of guidance for the day 8 initiation dose of paliperidone palmitate to avoid a missed doseMahesh N Samtani, Isaac Nuamah, Srihari Gopal, et al.
Journal of Affective Disorders|January 26, 2010
Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trialRoger S McIntyre, Miriam Cohen, Jun Zhao, et al.
Schizophrenia Research|August 8, 2022
Evaluation of major treatment failure in patients with recent-onset schizophrenia or schizophreniform disorder: A post hoc analysis from the Disease Recovery Evaluation and Modification (DREaM) studyLarry Alphs, Pamela Baker, Brianne Brown, et al.
Journal of Affective Disorders|June 12, 2010
Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension studyRoger S McIntyre, Miriam Cohen, Jun Zhao, et al.
Pageof 12

Showing results (51-60 of 120) with videos related to

Sort By:
Pageof 12
BMC Psychiatry|February 25, 2014
Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitateJennifer Kern Sliwa, Dong-Jing Fu, Cynthia A Bossie, et al.
Neuropsychiatric Disease and Treatment|September 8, 2012
Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophreniaJennifer Kern Sliwa, Cynthia A Bossie, Dong-Jing Fu, et al.
Innovations in Clinical Neuroscience|July 9, 2015
Comparing Injection Site Pain with Paliperidone Palmitate Versus First-Generation Depot Antipsychotics in Subjects with SchizophreniaSrihari Gopal, Teresa Palermo, Jennifer Kern Sliwa, et al.
International Clinical Psychopharmacology|October 12, 2013
Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparisonDong-Jing Fu, Cynthia A Bossie, Jennifer K Sliwa, et al.
BMC Psychiatry|May 17, 2011
Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trialCynthia A Bossie, Jennifer K Sliwa, Yi-Wen Ma, et al.
Expert Opinion on Pharmacotherapy|April 24, 2014
Onset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophreniaLarry Alphs, Cynthia A Bossie, Dong-Jing Fu, et al.
Neuropsychiatric Disease and Treatment|June 1, 2013
Expansion of guidance for the day 8 initiation dose of paliperidone palmitate to avoid a missed doseMahesh N Samtani, Isaac Nuamah, Srihari Gopal, et al.
Journal of Affective Disorders|January 26, 2010
Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trialRoger S McIntyre, Miriam Cohen, Jun Zhao, et al.
Schizophrenia Research|August 8, 2022
Evaluation of major treatment failure in patients with recent-onset schizophrenia or schizophreniform disorder: A post hoc analysis from the Disease Recovery Evaluation and Modification (DREaM) studyLarry Alphs, Pamela Baker, Brianne Brown, et al.
Journal of Affective Disorders|June 12, 2010
Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension studyRoger S McIntyre, Miriam Cohen, Jun Zhao, et al.
Pageof 12